Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2912602 | 0.94 | EPHX2 (0.52) | LMNAALDH1A1KDM4EEPHX2L3MBTL1 | |
| SCHEMBL6508631 | 0.91 | ALDH1A1 (0.49) | LMNAALDH1A1KDM4EEPHX2L3MBTL1 | |
| SCHEMBL4109675 | 0.89 | LMNA (0.54) | LMNAALDH1A1KDM4EEPHX2L3MBTL1 | |
| SCHEMBL13041145 | 0.88 | ALDH1A1 (0.47) | LMNAALDH1A1KDM4EEPHX2L3MBTL1 | |
| SCHEMBL3531395 | 0.87 | LTA4H (0.45) | ALDH1A1EPHX2L3MBTL1TDP1NAAA | |
| SCHEMBL24757124 | 0.86 | LMNA (0.51) | LMNAALDH1A1KDM4EEPHX2L3MBTL1 | |
| SCHEMBL9153257 | 0.86 | EPHX2 (0.46) | LMNAALDH1A1EPHX2L3MBTL1TDP1 | |
| SCHEMBL1988984 | 0.86 | EPHX2 (0.48) | LMNAEPHX2L3MBTL1TDP1SMN1; SMN2 | |
| SCHEMBL12147930 | 0.84 | EPHX2 (0.53) | LMNAALDH1A1KDM4EEPHX2L3MBTL1 | |
| SCHEMBL5543579 | 0.84 | HTT (0.46) | ALDH1A1EPHX2HTTNAAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250079-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2023-08-10 | — | — | US | disclosed |
| US-20230250079-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2023-08-10 | — | — | US | disclosed |
| WO-2021250194-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2021-12-16 | — | — | WO | disclosed |
| US-7803822-B2 | Triazole derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-28 | — | — | US | disclosed |
| US-7803822-B2 | Triazole derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-28 | — | — | US | disclosed |
| US-7803822-B2 | Triazole derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-28 | — | — | US | disclosed |
| US-7709509-B2 | Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| EP-2083006-A1 | Oxadiazolones, processes for their preparation and their use as pharmaceuticals | Sanofi-Aventis Deutschland GmbH (DE) | 2009-07-29 | — | — | EP | disclosed |
| EP-1740583-B1 | OXADIAZOLONE DERIVATIVES AS PPAR DELTA AGONISTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-01 | — | — | EP | disclosed |
| US-20090105253-A1 | Triazole Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20090105253-A1 | Triazole Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20090105253-A1 | Triazole Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20080262052-A1 | METHODS FOR THE TREATMENT OF METABOLIC AND GLUCOSE UTILIZATION DISORDERS THROUGH THE ADMINISTRATION OF OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20080255212-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-16 | — | — | US | disclosed |
| EP-1867331-A1 | TRIAZOLE DERIVATIVE AND THE USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-12-19 | — | — | EP | disclosed |
| EP-1867331-A1 | TRIAZOLE DERIVATIVE AND THE USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-12-19 | — | — | EP | disclosed |
| US-20070179191-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-02 | — | — | US | disclosed |
| EP-1740583-A1 | OXADIAZOLONE DERIVATIVES AS PPAR DELTA AGONISTS | Sanofi-Aventis Deutschland GmbH (DE) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005097786-A1 | OXADIAZOLONE DERIVATIVES AS PPAR DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250079-A1 | SMALL MOLECULE MODULATORS OF IL-17 | IL17A, IL2, IL23R | LMNA 3790/4885ALDH1A1 490/4885KDM4E 1325/4885 |
| US-20070179191-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS | PPARD, PPARA, PPARG | LMNA 3215/4885ALDH1A1 816/4885KDM4E 4578/4885 |
| US-20080255212-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS | PPARD, PPARG, PPARA | LMNA 2069/4885ALDH1A1 2018/4885KDM4E 3669/4885 |
| US-20080262052-A1 | METHODS FOR THE TREATMENT OF METABOLIC AND GLUCOSE UTILIZATION DISORDERS THROUGH THE ADMINISTRATION OF OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS | PPARD, PPARG, PPARA | LMNA 2976/4885ALDH1A1 951/4885KDM4E 4506/4885 |
| US-20090105253-A1 | Triazole Derivative and Use Thereof | F2R, HRH4, F2RL3 | LMNA 2020/4885ALDH1A1 3580/4885KDM4E 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.